CN113480672A - Exopolysaccharide of bacillus and application thereof - Google Patents
Exopolysaccharide of bacillus and application thereof Download PDFInfo
- Publication number
- CN113480672A CN113480672A CN202110836209.1A CN202110836209A CN113480672A CN 113480672 A CN113480672 A CN 113480672A CN 202110836209 A CN202110836209 A CN 202110836209A CN 113480672 A CN113480672 A CN 113480672A
- Authority
- CN
- China
- Prior art keywords
- paenibacillus
- exopolysaccharide
- linked
- residues
- glucuronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002444 Exopolysaccharide Polymers 0.000 title claims abstract description 73
- 241000193830 Bacillus <bacterium> Species 0.000 title description 2
- 241000179039 Paenibacillus Species 0.000 claims abstract description 62
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims abstract description 24
- 235000015099 wheat brans Nutrition 0.000 claims abstract description 21
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims abstract description 19
- 238000000855 fermentation Methods 0.000 claims abstract description 18
- 230000004151 fermentation Effects 0.000 claims abstract description 18
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 8
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 8
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 239000008103 glucose Substances 0.000 claims abstract description 7
- 229940097043 glucuronic acid Drugs 0.000 claims abstract description 7
- 230000002378 acidificating effect Effects 0.000 claims abstract description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 6
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 14
- 229940124622 immune-modulator drug Drugs 0.000 claims description 3
- 241000592795 Paenibacillus sp. Species 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 abstract description 43
- 229920001282 polysaccharide Polymers 0.000 abstract description 43
- 239000005017 polysaccharide Substances 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 17
- 230000007365 immunoregulation Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 33
- 239000000523 sample Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 150000002772 monosaccharides Chemical class 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 230000000242 pagocytic effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 206010057249 Phagocytosis Diseases 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008782 phagocytosis Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000002390 rotary evaporation Methods 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 3
- 239000000413 hydrolysate Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000001551 total correlation spectroscopy Methods 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000201493 Paenibacillus bovis Species 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Abstract
The invention discloses an extracellular polysaccharide of Paenibacillus and application thereof, wherein the extracellular polysaccharide is produced by inoculating a Paenibacillus sp strain with the preservation number of CGMCC NO.8333 to wheat bran for fermentation; the average weight molecular weight of the extracellular polysaccharide is 300,800-451,200 daltons, and the extracellular polysaccharide is an acidic heteropolysaccharide composed of glucuronic acid, glucose and fucose in a molar ratio of 1.55-1.60: 1: 1.63-1.72; the exopolysaccharide has a main chain composed of 1, 3-linked glucose residues, 1, 3-linked fucose residues, 1,3, 4-linked fucose residues and 1, 4-linked glucuronic acid residues, and is branchedThe point is positioned at the O-4 position of the 1,3, 4-linked fucose residue, and the branched chain is composed of glucuronic acid residues linked at the tail end and consists of a repeating structural unit shown in a formula I; in addition, the extracellular polysaccharide has a certain immunoregulation effect, and has good application prospects in food, medicine and related fields.
Description
Technical Field
The invention belongs to the field of microbial fermentation, and particularly relates to exopolysaccharide of bacillus sp and application thereof.
Background
Since the 60 s of the 20 th century, polysaccharide is considered as a broad-spectrum nonspecific immunostimulant, which can enhance the cellular immunity and humoral immunity of host cells, such as activating macrophages, T cells, B cells, NK cells and the like, activating complement, inducing interferon generation and the like, has the function of activating the nonspecific defense function of human bodies, and has good curative effects on antivirus, antitumor, antiradiation and the like.
According to the source, polysaccharides can be classified into animal polysaccharides, plant polysaccharides and microbial polysaccharides, wherein the microbial polysaccharides are produced by microorganisms metabolizing carbohydrates, generally, the base materials for metabolism are artificially synthesized, such as MRS, TYC, etc., while the research on synthesizing the microbial polysaccharides using natural base materials, especially agricultural processing by-products (such as wheat bran, etc.) is relatively small.
On the other hand, in the field, the types of the microbial exopolysaccharides which are mature and can be popularized and applied in practice are not many, and the need of researching new exopolysaccharides exists in production and scientific research so as to enrich the types of the microbial exopolysaccharides with excellent performance and wide application.
Disclosure of Invention
The invention aims to provide an extracellular polysaccharide of Paenibacillus and application thereof, wherein the extracellular polysaccharide has various biological effects and has good application prospects in the fields of food, medicine and the related fields. The invention mainly solves the technical problems through the following technical scheme.
The invention provides an extracellular polysaccharide of Paenibacillus, which is produced by inoculating a Paenibacillus sp strain with the preservation number of CGMCC NO.8333 to wheat bran for fermentation. The strain is preserved in China general microbiological culture Collection center (CGMCC) in 2013, 10 months and 14 days, and the preservation address is as follows: west road No. 1, north chen, chaoyang district, beijing, zip code: 100101.
Preferably, the average weight molecular weight of the exopolysaccharide of the paenibacillus is 300,800-451,200 daltons.
Preferably, the exopolysaccharide is an acidic heteropolysaccharide composed of glucuronic acid, glucose and fucose in a molar ratio of 1.55-1.60: 1: 1.63-1.72.
Preferably, the exopolysaccharide has a backbone composed of 1, 3-linked glucose residues, 1, 3-linked fucose residues, 1,3, 4-linked fucose residues and 1, 4-linked glucuronic acid residues, a branch point at the O-4 position of the 1,3, 4-linked fucose residues, and a branch chain composed of terminally linked glucuronic acid residues.
Preferably, the exopolysaccharide consists of a repeating structural unit represented by formula I.
The invention also provides application of the exopolysaccharide of the Paenibacillus in the fields of food and medicine.
The invention also provides application of the exopolysaccharide of the Paenibacillus in preparing an immunomodulatory drug.
Preferably, the paenibacillus has exopolysaccharide concentration of less than 100 μ g/mL.
Compared with the prior art, the invention has the positive improvement effects that:
the technical scheme of the invention discloses the exopolysaccharide of the paenibacillus with a definite and unique structure for the first time, and the exopolysaccharide is safe and has various biological effects, such as enhancing the phagocytic function of macrophages and promoting the macrophages to release cytokines, so that the exopolysaccharide has obvious technical advantages as a high molecular substance generated by microorganisms, and has good application prospects in the fields of food, medicine and related fields.
Drawings
FIG. 1 is gel chromatography elution curve diagram of crude product of CGMCC No.8333 exopolysaccharide
FIG. 2 is a high performance gel filtration chromatogram of CGMCC No.8333 exopolysaccharide
FIG. 3 is 1H-NMR chromatogram of CGMCC No.8333 exopolysaccharide
FIG. 4 is a 13C-NMR chromatogram of CGMCC No.8333 exopolysaccharide
FIG. 5 is the H-H COSY chromatogram of CGMCC No.8333 exopolysaccharide
FIG. 6 is HSQC chromatogram of CGMCC No.8333 exopolysaccharide
FIG. 7 is TOCSY chromatogram of CGMCC No.8333 exopolysaccharide
FIG. 8 is HMBC chromatogram of CGMCC No.8333 exopolysaccharide 1
FIG. 9 shows HMBC chromatogram of CGMCC No.8333 exopolysaccharide
FIG. 10 shows NOESY chromatogram of CGMCC No.8333 exopolysaccharide
FIG. 11 shows the effect of CGMCC No.8333 exopolysaccharide on RAW264.7 cells
FIG. 12 shows the effect of CGMCC No.8333 exopolysaccharide on phagocytic ability of RAW264.7 cells
FIG. 13 shows the effect of CGMCC No.8333 exopolysaccharide on NO release from RAW264.7 cells
FIG. 14 shows the effect of CGMCC No.8333 exopolysaccharide on TNF-alpha secretion of RAW264.7 cells
FIG. 15 shows the effect of CGMCC No.8333 exopolysaccharide on IL-1 beta secretion of RAW264.7 cells
FIG. 16 shows the effect of CGMCC No.8333 exopolysaccharide on IL-6 secretion of RAW264.7 cells
Detailed Description
The exopolysaccharide of the Paenibacillus is produced by inoculating a Paenibacillus (Paenibacillus sp.) strain with the preservation number of CGMCC NO.8333 to wheat bran for fermentation.
In the invention, the wheat bran is prepared manually, the prepared wheat bran for fermentation comprises 1-5% by mass, preferably 2-4% by mass and more preferably 3% by mass of water. The preparation method of the wheat bran for fermentation may include the following steps: adding wheat bran and distilled water into the triangular flask, uniformly mixing, heating and boiling, sterilizing at 95-125 ℃ for 5-25 min, and cooling to obtain the wheat bran-distilled water.
The average weight molecular weight of the extracellular polysaccharide of the paenibacillus is 300,800-451,200 daltons, and the extracellular polysaccharide is an acidic heteropolysaccharide consisting of glucuronic acid, glucose and fucose in a molar ratio of 1.55-1.60: 1: 1.63-1.72. The main chain of the extracellular polysaccharide is composed of 1, 3-linked glucose residues, 1, 3-linked fucose residues, 1,3, 4-linked fucose residues and 1, 4-linked glucuronic acid residues, a branch point is positioned at the O-4 position of the 1,3, 4-linked fucose residues, a branch chain is composed of terminal linked glucuronic acid residues, and the branch chain is composed of a repeating structural unit shown in a formula I.
The invention also provides application of the exopolysaccharide of the paenibacillus in the fields of food and medicine. Research shows that the microbial exopolysaccharide has bioactivity, such as immunological activity, tumor resistance, oxidation resistance, tumor resistance, intestinal flora regulation, etc. and may be used in food, medicine and other fields. Immunomodulation is one of the most important biological activities of polysaccharides and is a non-specific class of immunomodulators. The immune system is a guard system for resisting invasion of pathogenic microorganisms and clearing variant cells in the organism and mainly comprises immune organs, immune cells and immune molecules. In a normal organism, the immune system maintains a dynamic balance, so that the organism is kept stable. However, when the immune system is disturbed, a series of diseases are induced, and the normal physiological functions of the body are impaired. Researches show that the immunoregulation effect of the exopolysaccharide on organisms mainly comprises the steps of activating macrophages, activating immune cells such as B cells and T cells, entering the cells through cell surface receptor recognition, improving the phagocytic and secretory capacity of the cells, activating complement, activating a reticuloendothelial system and promoting the development of immune organs. In the invention, the exopolysaccharide synthesized by the paenibacillus bovis CGMCC NO.8333 has NO cytotoxicity when the concentration is lower than 100 mug/mL, can activate RAW264.7 cells and enhance the phagocytosis capability of the cells, improves the expression of NO, TNF-alpha, IL-1 beta and IL-6 cytokines by activating the RAW264.7 cells, and has good immunoregulation effect.
The invention also provides application of the exopolysaccharide of the Paenibacillus in preparing an immunomodulatory drug.
The following examples further illustrate the above embodiments, but do not therefore limit the invention within the scope of the examples described. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.
In the examples below, all the starting materials are commercially available and meet the relevant national standards.
Example 1 preparation of Paenibacillus exopolysaccharides
1. Materials and methods
(a) Preparation of seeds (fermentation strain): dissolving the freeze-dried powder of the paenibacillus CGMCC No.8333 by using a small amount of sterile distilled water, marking a ring by using an inoculating ring on a solid culture medium containing 1% (w/w) of skim milk and 1.5% (w/v) of agar (purchased from Chinese pharmacy group, China), carrying out aerobic culture at 30 ℃ for 48h, taking out, selecting a single colony by using the inoculating ring, inoculating into 10mL of liquid culture medium containing 10% (w/w) of skim milk, and carrying out shaking culture at 30 ℃ and 180rpm for 24h to obtain seeds for fermentation.
(b) Preparing a wheat bran culture medium: adding 1.8g wheat bran (commercially available) and 58.2mL distilled water into a 250mL triangular flask, mixing, heating to boil, sterilizing at 110 deg.C for 15min, and cooling to room temperature to obtain the desired wheat bran culture medium.
2. Preparation of paenibacillus extracellular polysaccharide crude product
The paenibacillus CGMCC No.8333 seeds are aseptically inoculated into the wheat bran culture medium according to the inoculum size of 3 percent (v/v, the volume percent of the seed liquid accounts for the fermentation liquid, the same is applied below), and the fermentation liquid is obtained after shaking culture at 26 ℃ and 180rpm for 48 hours. Centrifuging the fermentation liquid at 15,000rpm for 10min, collecting supernatant, heating and boiling for 10min, cooling to room temperature, slowly adding anhydrous ethanol (purchased from Chinese medicine group, China) with three times volume, refrigerating and standing for 24h, collecting precipitate, centrifuging at 15,000rpm for 10min, completely re-dissolving with small amount of distilled water, and freeze-drying to obtain crude Paenibacillus extracellular polysaccharide A.
3. Preparation of Paenibacillus exopolysaccharide (single component)
250mg of the crude Paenibacillus exopolysaccharide A is dissolved in 25mL of Tris-HCl buffer solution (50mM, pH7.6) (purchased from the national pharmaceutical industry, China), loaded on a chromatographic column of a DEAE-Sepharose Fast Flow (purchased from GE, USA) which is pre-loaded and well balanced by a constant Flow pump, and then is subjected to isocratic elution by sequentially using Tris-HCl buffer solution (50mM, pH7.6), buffer solution containing 0.2mol/L NaCl and 0.4mol/L NaCl, wherein the elution speed is 1.5mL/min, and eluent is collected (8 mL is collected per tube) by an automatic fraction collector (purchased from Shanghai Qingpu West apparatus factory, China).
Detecting the polysaccharide content in the eluent of each tube by using a sulfuric acid-phenol method, merging and collecting a third component peak (185-205 tubes in figure 1, the abscissa is the number of the tubes and the ordinate is the light absorption value in figure 1), putting into a dialysis bag with the molecular weight cutoff of 14,000 daltons, dialyzing with deionized water for 72 hours to remove buffer salts, changing water once every 12 hours, and freeze-drying to obtain the polysaccharide with a single component, namely the paenibacillus extracellular polysaccharide, namely EPS-1.
EXAMPLE 2 preparation of Paenibacillus exopolysaccharides
1. Materials and methods
(a) Preparation of seeds (fermentation strain): the same as in example 1.
(b) Preparing a wheat bran culture medium: adding 0.6g of wheat bran and 59.4mL of distilled water into a 250mL triangular flask, uniformly mixing, heating to boil, sterilizing at 125 ℃ for 5min, and cooling to room temperature to obtain the required wheat bran culture medium.
2. Preparation of paenibacillus extracellular polysaccharide crude product
Aseptically inoculating paenibacillus CGMCC No.8333 seeds with the inoculum size of 5 percent into the wheat bran culture medium, and carrying out shaking culture at 37 ℃ and 300rpm for 12h to obtain fermentation liquor. Centrifuging the fermentation liquor at 15,000rpm for 10min, taking the supernatant, heating and boiling for 10min, cooling to room temperature, slowly adding anhydrous ethanol with the volume being three times that of the supernatant, refrigerating and standing for 24h, taking out the product, centrifuging at 15,000rpm for 10min, taking the precipitate, completely re-dissolving the precipitate with a small amount of distilled water, and freeze-drying to obtain a crude paenibacillus extracellular polysaccharide B.
3. Preparation of Paenibacillus exopolysaccharide (single component)
The crude Paenibacillus exopolysaccharide B is separated by the method described in reference example 1, and the exopolysaccharide EPS-2 with a single component of Paenibacillus is obtained.
Example 3 preparation of Paenibacillus exopolysaccharides
1. Materials and methods
(a) Preparation of seeds (fermentation strain): the same as in example 1.
(b) Preparing a wheat bran culture medium: adding 3g of wheat bran and 57mL of distilled water into a 250mL triangular flask, uniformly mixing, heating and boiling, placing at 95 ℃ for sterilization for 25min, and cooling to room temperature to obtain the required wheat bran culture medium.
2. Preparation of paenibacillus extracellular polysaccharide crude product
Aseptically inoculating paenibacillus CGMCC No.8333 seeds with the inoculum size of 1% in the wheat bran culture medium, and performing shaking culture at 20 ℃ and 100rpm for 72h to obtain a fermentation liquid. Centrifuging the fermentation liquor at 15,000rpm for 10min, taking the supernatant, heating and boiling for 10min, cooling to room temperature, slowly adding anhydrous ethanol with the volume being three times that of the supernatant, refrigerating and standing for 24h, taking out the product, centrifuging at 15,000rpm for 10min, taking the precipitate, completely re-dissolving the precipitate with a small amount of distilled water, and freeze-drying to obtain a crude paenibacillus extracellular polysaccharide C.
3. Preparation of Paenibacillus exopolysaccharide (single component)
The crude Paenibacillus exopolysaccharide C is separated by the method described in reference example 1, and the exopolysaccharide EPS-3 with a single component of Paenibacillus is obtained.
Example 4 Paenibacillus exopolysaccharide unicity validation
Weighing 5mg of EPS-1, EPS-2 and EPS-3 samples, respectively dissolving in 5mL of ultrapure water to prepare 1mg/mL polysaccharide solution, filtering with 0.45 μm filter membrane, and introducing into Agilent 1100 high performance liquid chromatograph (from Agilent, USA) for analysis under chromatographic conditions: RID detector, TSK-Gel G6000PWXL (available from Tosoh Biotech Co., Ltd., Japan) as chromatographic column, and 0.1mol/L NaNO as mobile phase3And (3) solution. The flow rate was set at 0.6mL/min, the column temperature was set at 35 ℃ and the amount of sample was set at 20. mu.L, and the purity (unity) was judged from the peak pattern.
Wherein, the high-efficiency gel filtration chromatogram of the EPS-1 sample is shown in figure 2 (the chromatograms of EPS-2 and EPS-3 are similar to each other), a symmetrical chromatographic peak is presented in the retention time of 14-15min, the chromatographic peak in 21min is a mobile phase peak, and the results show that the EPS-1, EPS-2 and EPS-3 samples are all homogeneous polysaccharide components.
Example 5 determination of Paenibacillus exopolysaccharide molecular weight
Dextran of different molecular weights was used as standard: STD-1(Mw ═ 5,000), STD-2(Mw ═ 12,000), STD-3(Mw ═ 50,000), STD-4(Mw ═ 270,000), STD-5(Mw ═ 670,000). Respectively dissolving the series of standard polysaccharides and EPS-1, EPS-2 and EPS-3 samples in a mobile phase (0.1mol/L NaNO)3Solution) 1mg/mL solution was obtained, filtered through 0.45 μm filter and analyzed by Agilent 1100 hplc using the same chromatographic conditions as in example 4. And drawing a standard curve by taking the logarithm LgMw of the molecular weight of the standard polysaccharide as an abscissa and the retention time tR as an ordinate to obtain a linear regression equation of the logarithm of the molecular weight and the retention time. The molecular weight of the sample can be calculated from the regression equation and the results are shown in the following table.
TABLE 1 Paenibacillus extracellular polysaccharide molecular weight determination
And (4) conclusion: the average weight molecular weight of the paenibacillus extracellular polysaccharide is 300,800-451,200 daltons.
Example 6 determination of monosaccharide composition of Paenibacillus exopolysaccharides
(1) Hydrolysis of polysaccharide samples
2.0mg of EPS-1, EPS-2 and EPS-3 samples are respectively placed in an ampoule bottle, 3mL of 2mol/L trifluoroacetic acid (TFA) is added, and hydrolysis is carried out for 5h at 110 ℃ after sealing. Cooling the hydrolysate, performing rotary evaporation at 45 ℃ under reduced pressure until the hydrolysate is dried, adding methanol to continue the rotary evaporation, and repeating the rotary evaporation for several times to remove excessive TFA to obtain the EPS hydrolysate.
(2) Derivatization of hydrolyzed samples and mixed monosaccharide standards
The EPS hydrolysate was dissolved in 1mL of water to obtain a sample solution to be derivatized. Taking 1mL of the sample solution or a mixed standard solution of 9 monosaccharides (0.5mg/mL, rhamnose, fucose, glucuronic acid, galactose, glucose, mannose, galacturonic acid, arabinose and xylose), adding 1mL of 0.6 mol/L NaOH solution and 1mL of 0.5mol/L PMP methanol solution, uniformly mixing to completely dissolve a solid product, and placing in an oven at 70 ℃ for reaction for 100 min. Cooling to room temperature, adding 0.3 mol/L HCl dropwise to adjust to neutrality, extracting with chloroform for 3 times, collecting water phase, filtering with 0.45 μm filter membrane, and analyzing by HPLC sample injection.
(3) Chromatographic conditions
Agilent 1260 high performance liquid chromatograph (from Agilent, USA) equipped with DAD detector and Agilent Eclipse XDB-C18 column (from Agilent, USA) was used. The column temperature was set at 30 ℃ and the amount of sample was 20. mu.L, and the detection wavelength was 250nm with a mobile phase acetonitrile: 0.1mol/L phosphate buffer (pH 6.8): 16:84 (V/V).
(4) Data analysis
The monosaccharide composition of the polysaccharide samples was determined with reference to retention times according to different monosaccharide standards (purchased from sigma, usa). And determining the molar ratio of the monosaccharides in the polysaccharide sample according to the peak area ratio of the monosaccharide composition. The results are shown in Table 2.
TABLE 2 molar ratio of monosaccharides for Paenibacillus exopolysaccharides
Glucuronic acid | Glucose | Fucose sugar | |
EPS-1 (in terms of molar ratio) | 1.58 | 1 | 1.66 |
EPS-2 (in terms of molar ratio) | 1.55 | 1 | 1.63 |
EPS-3 (in terms of molar ratio) | 1.60 | 1 | 1.72 |
And (4) conclusion: the exopolysaccharide of the paenibacillus is an acidic heteropolysaccharide consisting of glucuronic acid, glucose and fucose in a molar ratio of 1.55-1.60: 1: 1.63-1.72.
Example 7 determination of mode of Paenibacillus exopolysaccharide ligation
(1) Methylation analysis
Uronic acid reduction: adopts carbodiimide-sodium borohydride method (EDC-NaBH)4) Reducing uronic acid, the reaction is divided into two stages, the first stage: a50 mg sample of EPS-1 was dissolved in 6mL of ultrapure water and stirred until it was completely dissolved. 500mg of EDC is added into the solution twice at intervals of 30min, the pH is controlled to be between 4.5 and 4.8 by 0.1mol/L HCl, and the whole reaction process needs 3 hours. And a second stage: 8mL of 2mol/L NaBH is dripped into the system within 40min4Controlling the pH value of the system to be about 7.0, continuing the reaction for 1h after the dripping is finished, and placing the product in a dialysis bag (entrapping molecules)3500Da) for 24 h. The above steps are repeated 4 times, and PMP-HPLC is used to detect complete reduction of uronic acid.
Methylation: taking 20mg of the dried polysaccharide sample with completely reduced uronic acid, placing the dried polysaccharide sample in a 10mL reaction bottle, quickly adding 3mL of anhydrous dimethyl sulfoxide at room temperature, sealing, magnetically stirring for 30min, dissolving the sample with ultrasonic assistance, then quickly adding 50mg of dried NaOH powder, sealing and stirring until most of NaOH is dissolved, carrying out ice bath for 5min, slowly dropwise adding 1mL of methyl iodide within 30min, stirring at room temperature in a dark place, continuing to react for 30min, and finally adding 1mL of ultrapure water to terminate the reaction. Putting the product in a dialysis bag for running water dialysis for 24h, and repeating the steps after rotary evaporation to dryness. After methylation for many times, taking a small amount of samples for infrared spectrum detection, and if the O-H stretching vibration absorption peak of the polysaccharide sample at 3400-3000cm < -1 > disappears, indicating that the polysaccharide sample is completely methylated; if the sample is not completely methylated, the reaction is continued until the sample is completely methylated.
Hydrolysis and acetylation: 2mg of a completely methylated EPS-1 sample was placed in an ampoule, 3mL of 2mol/L TFA was added and sealed, and after hydrolysis at 110 ℃ in a closed environment for 4h, methanol was added and rotary evaporation was carried out several times under reduced pressure to completely remove TFA. After spin-drying, 3mL of ultrapure water was added for dissolution, and 50mg of NaBH was added4The reaction was magnetically stirred at room temperature for 3 h. After the reaction, acetic acid was added until the solution became weakly acidic (pH 5), methanol was added and the solution was rotary evaporated to dryness, and this was repeated several times to sufficiently remove boric acid. The obtained solid is dried in an oven at 100 ℃ for 10min, 3mL of acetic anhydride is added, the reaction is carried out at 100 ℃ for 100min, and after the reaction is finished, toluene (3mL) is added for multiple times to co-evaporate and remove the excessive acetic anhydride. The product was dissolved in chloroform (5mL), extracted 3 times with ultrapure water (5 mL. times.3), the chloroform layer was recovered, anhydrous sodium sulfate powder was added to remove water, the mixture was allowed to stand for 30min, evaporated to dryness under reduced pressure, dissolved in 0.5mL of chloroform, filtered through a 0.22 μm organic filter and analyzed by GC-MS.
GC-MS conditions: the instrument model is as follows: agilent 7820A/5977GC-MS (available from Agilent, USA); the type of the chromatographic column: HP-5 capillary column; temperature programming: the initial temperature is 120 ℃, the temperature is increased to 250 ℃ after the temperature is maintained for 2min, the temperature increase rate is 5 ℃/min, and the temperature is maintained for 10 min; the sample inlet adopts a split mode, and the split ratio is 3: 1; the amount of sample was 1. mu.L. The mass spectrum ion source is an EI source, the voltage of the ion source is 70eV, and the temperature is 180 ℃.
And (3) data analysis: by comparing the EI-MS spectrum obtained by GC-MS with the standard PMAA spectrum and combining the results of monosaccharide composition, the connection mode of each sugar residue of the EPS-1 after reduction can be determined to be 1, 3-connected fucose residue, 1,3, 4-connected fucose residue, 1, 3-connected glucose residue and 1, 4-connected glucuronic acid residue, and the terminal connected glucuronic acid residue.
(2) Nuclear magnetic resonance spectroscopy
20mg of EPS-1 sample is taken and 0.5mL of D is used2O dissolved, transferred to a clean NMR tube and chromatographed on a 600MHz NMR spectrometer (from Bruker, Switzerland).
To pair1H-NMR (FIG. 3),13After comprehensive analysis of C-NMR (FIG. 4), H-H COSY (FIG. 5), HSQC (FIG. 6), TOCSY (FIG. 7), HMBC (FIG. 8, FIG. 9) and NOESY (FIG. 10), it was found that the EPS-1 main chain is composed of 1, 3-linked glucose residues, 1, 3-linked fucose residues, 1,3, 4-linked fucose residues and 1, 4-linked glucuronic acid residues, the branch point is located at the O-4 position of the 1,3, 4-linked fucose residues, and the branch chain is composed of terminally linked glucuronic acid residues.
In conclusion, the paenibacillus exopolysaccharide is composed of the repeated structural units shown in the formula I.
Effect example 1 Effect of Paenibacillus exopolysaccharides on cell growth
The concentration of RAW264.7 cells was adjusted to 1X 104one/mL, inoculated in 96-well cell culture plates at 200. mu.L/well, 37 ℃ with 5% CO2Culturing is carried out under the conditions. After the cells are attached to the wall, the culture solution is discarded, EPS-1 solutions (0, 6.25, 12.5, 25, 50, 100, 200, 400 and 600 mu g/mL) with different concentrations are respectively added into each well, LPS (1 mu g/mL) is used as a positive control, 200 mu L/well is used, and 5 plateaus are set at each concentrationAnd (4) forming holes. After 24 hours of incubation, the well plate was aspirated, 30. mu.L of sterilized MTT solution (5mg/mL) was added to each well, the well plate was aspirated after 4 hours of incubation, 200. mu.L of DMSO was added to each well, the purple crystals in the well plate were sufficiently dissolved by shaking, and then the absorbance (OD) was measured at 492nm using a microplate reader (purchased from Molecular Devices, USA) and the survival rate of the cells under the administration conditions was calculated by the following equation, as shown in FIG. 11.
Survival%Experimental group/ODControl group×100%
When the concentration of EPS-1 is respectively 6.25, 12.5, 25, 50 and 100 mu g/mL, the survival rate of RAW264.7 cells is higher than that of a blank control group, which is respectively 120.92 +/-1.73%, 120.637 +/-3.80%, 121.15 +/-2.37%, 116.05 +/-3.24% and 109.70 +/-3.16%; when the administration concentration is increased to 200 mug/mL, the survival rate of RAW264.7 cells is reduced and is lower than that of a blank control group; when the administration concentration reached the maximum concentration, i.e., 600. mu.g/mL, the viability of RAW264.7 cells was significantly lower than that of the blank control group, which was only 62.74 + -2.94%. The experimental result shows that the EPS-1 has no cytotoxicity to RAW264.7 cells within the range of 6.25-100 mu g/mL.
And (4) conclusion: when the concentration is lower than 100 mu g/mL, the Paenibacillus exopolysaccharide is safe to cells.
Effect example 2 Effect of Paenibacillus exopolysaccharides on phagocytic Capacity of RAW264.7 cells
The concentration of RAW264.7 cells was adjusted to 1X 104one/mL, inoculated in 96-well cell culture plates at 200. mu.L/well, 37 ℃ with 5% CO2The culture was performed under conditions such that the culture medium was discarded after the cells were attached to the wall, and 100. mu.L each of EPS-1 solution (0, 6.25, 12.5, 25, 50, 100. mu.g/mL) and LPS (1. mu.g/mL) was added to each well at different concentrations, and 5 parallel wells were provided for each concentration. After 24h of culture, 0.08% ready-prepared neutral red solution was added, the incubator was incubated for 1h, the solution was aspirated after removal, rinsed 2 times with PBS, lysed by adding lysis buffer (glacial acetic acid: ethanol 1: 1) for 1h, absorbance was measured at 492nm with a microplate reader, and the phagocytosis rate of each group was calculated by the following formula, and the results are shown in fig. 12.
Percent cell phagocytosis ═ ODExperimental group/ODControl group×100%
When the concentration of EPS-1 is respectively 6.25, 12.5, 25, 50 and 100 mug/mL, the phagocytosis rate of each administration treatment group is respectively 105.63 +/-2.17%, 109.11 +/-2.43%, 109.91 +/-2.75%, 119.42 +/-1.84% and 126.25 +/-2.77%, which are higher than those of the blank control group and are significantly different. In the above concentration range, the phagocytic activity of RAW264.7 cells gradually increased with increasing administration concentration, and the phagocytic ratio of cells at administration concentration of 100 μ g/mL approached that of the positive control group (129.03 ± 3.13%).
And (4) conclusion: the paenibacillus extracellular polysaccharide is 6.25-100 mu g/mL, and can activate RAW264.7 cells and enhance the phagocytosis capacity.
Effect example 3 Effect of Paenibacillus exopolysaccharides on cytokine Release from RAW264.7 cells
The concentration of RAW264.7 cells was adjusted to 5X 105mL, seeded in 96-well cell culture plates at 200. mu.L/well, 37 ℃, 5% CO2Culturing is carried out under the conditions. After the cells are attached to the wall, the culture solution is discarded, and 100. mu.L of EPS-1 solution (0, 6.25, 12.5, 25, 50, 100, 200, 400, 600. mu.g/mL) and LPS (1. mu.g/mL) with different concentrations are respectively added into each well for 24h of culture, wherein 2 parallel wells are arranged at each concentration. 50 μ L of cell supernatant was collected from each well and the corresponding cytokines were detected using NO kit, TNF- α ELISA kit, IL-1 β ELISA kit and IL-6ELISA kit (purchased from ELISA, USA), respectively.
The results are shown in FIG. 13(NO), FIG. 14 (TNF-alpha), FIG. 15(IL-1 beta) and FIG. 16(IL-6), and the secretion levels of NO, TNF-alpha, IL-1 beta and IL-6 of RAW264.7 increase dose-dependently after adding different concentrations of EPS-1 for a certain period of time, which indicates that the paenibacillus exopolysaccharide can activate RAW264.7 cells, increase the expression of the above cytokines and promote the immunomodulatory effect.
The extracellular polysaccharide of Paenibacillus and the application thereof provided by the invention are described in detail above. The principles and embodiments of the present invention are explained herein using specific examples, which are presented only to assist in understanding the method and its core concepts. It should be noted that, for those skilled in the art, it is possible to make various improvements and modifications to the present invention without departing from the principle of the present invention, and those improvements and modifications also fall within the scope of the claims of the present invention.
Claims (8)
1. The exopolysaccharide of the Paenibacillus is characterized in that the exopolysaccharide is produced by inoculating a Paenibacillus (Paenibacillus sp.) strain with the preservation number of CGMCC NO.8333 to wheat bran for fermentation.
2. The exopolysaccharide of Paenibacillus according to claim 1, wherein the average weight molecular weight of the exopolysaccharide is 300,800-451,200 daltons.
3. The exopolysaccharide of paenibacillus according to claim 1, which is an acidic heteropolysaccharide composed of glucuronic acid, glucose and fucose in a molar ratio of 1.55-1.60: 1: 1.63-1.72.
4. Exopolysaccharide of paenibacillus according to claim 1, characterized in that the main chain of the exopolysaccharide is composed of 1, 3-linked glucose residues, 1, 3-linked fucose residues, 1,3, 4-linked fucose residues and 1, 4-linked glucuronic acid residues, the branch point is located at the O-4 position of the 1,3, 4-linked fucose residues, and the branch chain is composed of terminally linked glucuronic acid residues.
6. The exopolysaccharide of Paenibacillus of claim 1 for use in the fields of food and medicine.
7. Use of exopolysaccharides of paenibacillus according to claim 1 in the preparation of immunomodulatory drugs.
8. The use according to claim 6 or 7, wherein the paenibacillus has an exopolysaccharide concentration of less than 100 μ g/mL.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110836209.1A CN113480672B (en) | 2021-07-23 | 2021-07-23 | Exopolysaccharide of bacillus and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110836209.1A CN113480672B (en) | 2021-07-23 | 2021-07-23 | Exopolysaccharide of bacillus and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113480672A true CN113480672A (en) | 2021-10-08 |
CN113480672B CN113480672B (en) | 2023-03-17 |
Family
ID=77943257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110836209.1A Active CN113480672B (en) | 2021-07-23 | 2021-07-23 | Exopolysaccharide of bacillus and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113480672B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023088791A1 (en) | 2021-11-22 | 2023-05-25 | Basf Se | Paenibacillus strains producing low amounts of dab comprising compounds. |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201226571A (en) * | 2010-12-31 | 2012-07-01 | Univ Tamkang | Production method of microbial exopolysaccharide |
WO2015011266A1 (en) * | 2013-07-25 | 2015-01-29 | Technische Universität München | Method for producing exopolysaccharides, products and uses thereof |
CN104450655A (en) * | 2014-12-09 | 2015-03-25 | 光明乳业股份有限公司 | Preparation method and product of paenibacillus chymosin |
CN104911167A (en) * | 2015-07-13 | 2015-09-16 | 光明乳业股份有限公司 | Paenibacillus damxungensis sp.nov. CGMCC No.8333 chymosin and preparation method |
CN112852902A (en) * | 2021-01-19 | 2021-05-28 | 南昌大学 | Enterococcus extracellular polysaccharide with immunoregulation effect and preparation method and application thereof |
-
2021
- 2021-07-23 CN CN202110836209.1A patent/CN113480672B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201226571A (en) * | 2010-12-31 | 2012-07-01 | Univ Tamkang | Production method of microbial exopolysaccharide |
WO2015011266A1 (en) * | 2013-07-25 | 2015-01-29 | Technische Universität München | Method for producing exopolysaccharides, products and uses thereof |
CN104450655A (en) * | 2014-12-09 | 2015-03-25 | 光明乳业股份有限公司 | Preparation method and product of paenibacillus chymosin |
CN104911167A (en) * | 2015-07-13 | 2015-09-16 | 光明乳业股份有限公司 | Paenibacillus damxungensis sp.nov. CGMCC No.8333 chymosin and preparation method |
CN112852902A (en) * | 2021-01-19 | 2021-05-28 | 南昌大学 | Enterococcus extracellular polysaccharide with immunoregulation effect and preparation method and application thereof |
Non-Patent Citations (4)
Title |
---|
储炬等: "《现代生物工艺学 下》", 31 March 2008, 华东理工大学出版社 * |
吴兴壮等: "《乳酸菌及其发酵食品》", 31 May 2021 * |
崔燕丽等: ""Paenibacillus bovis BD3526 产胞外多糖的培养条件优化"", 《食品与发酵工业》 * |
花榜清等: ""牛类芽孢杆菌BD3526发酵液中抗菌物质的特性及初步分离"", 《乳业科学与技术》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023088791A1 (en) | 2021-11-22 | 2023-05-25 | Basf Se | Paenibacillus strains producing low amounts of dab comprising compounds. |
Also Published As
Publication number | Publication date |
---|---|
CN113480672B (en) | 2023-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106635924B (en) | Preparation and application of lactobacillus rhamnosus exopolysaccharide | |
CN111978421A (en) | Phellinus igniarius polysaccharide and preparation and application thereof | |
Liu et al. | Characterization and chemical modification of PLN-1, an exopolysaccharide from Phomopsis liquidambari NJUSTb1 | |
CN113278091A (en) | Porphyridium polysaccharide and preparation method and application thereof | |
CN103724446A (en) | Exopolysaccharide of lactobacillus rhamnosus, and preparation method and application thereof | |
CN105147715B (en) | A kind of new application of Paecilomyces hepiali chen neutrality exocellular polysaccharide | |
CN113480672B (en) | Exopolysaccharide of bacillus and application thereof | |
Liu et al. | Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation | |
CN111363056B (en) | Rhodopseudomonas palustris exopolysaccharide and preparation method and application thereof | |
CN112724270A (en) | Low-molecular-weight alfalfa polysaccharide, preparation method thereof and application of low-molecular-weight alfalfa polysaccharide in regulating intestinal flora | |
CN114134188B (en) | Method for synthesizing extracellular polysaccharide by fermenting wheat bran | |
CN103757070A (en) | Extracellular polysaccharide with immunomodulatory effect and preparation method and application thereof | |
WO2023066163A1 (en) | Exopolysaccharide separated from lactobacillus delbrueckii and streptococcus thermophilus fermented yoghourt and application thereof | |
CN114149936B (en) | Strain for synthesizing extracellular polysaccharide by fermenting wheat bran | |
CN112568445B (en) | Fucoidan with prebiotic effect, and preparation method and application thereof | |
CN112920287B (en) | Amomum villosum polysaccharide with immunoregulation effect and preparation method and application thereof | |
CN114027510A (en) | Chlorella pyrenoidosa polysaccharide mixture, preparation method thereof and application of chlorella pyrenoidosa polysaccharide mixture as novel prebiotics | |
CN113817076A (en) | Lactobacillus helveticus polysaccharide SGP2-1 with immunoregulatory activity and preparation method and application thereof | |
CN115043956B (en) | Sambucus williamsii polysaccharide, polysaccharide composition and application thereof | |
CN117384308A (en) | Radix tetrastigme polysaccharide prepared based on Phellinus fermentation and application thereof | |
CN115947876B (en) | beta-D-galactoglucan and preparation and application thereof | |
CN116925962B (en) | Bacillus amyloliquefaciens JM033 exopolysaccharide with intestinal flora and immunoregulatory function and application thereof | |
CN117964787A (en) | Extracellular polysaccharide derived from lactobacillus rhamnosus strain BD 4047 and preparation method and application thereof | |
CN111704679B (en) | Beta-glucan of hericium erinaceus fermentation mycelium and preparation method and application thereof | |
CN110305816B (en) | Streptococcus thermophilus IMAU20756 and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |